ArQule Inc. (ARQL)

[stockguard]

In a report released today, Jotin Marango from Roth Capital maintained a Buy rating on Arqule (ARQL – Research Report), with a price target of $10. The company’s shares closed on Friday at $6.05.

Marango commented:

“We remain high-conviction buyers of ARQL shares and are raising our PT to $10.”

According to TipRanks.com, Marango has currently no stars on a ranking scale of 0-5 stars, with an average return of -5.4% and a 41.2% success rate. Marango covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals Inc, Syros Pharmaceuticals, and Aimmune Therapeutics.

Currently, the analyst consensus on Arqule is a Strong Buy with an average price target of $7.69.

The company has a one-year high of $7.21 and a one-year low of $2.23. Currently, Arqule has an average volume of 1.37M.

Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ARQL in relation to earlier this year. Earlier this month, Ronald M. Lindsay, a Director at ARQL bought 10,000 shares for a total of $38,700.

ArQule, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutics to treat cancers and rare diseases. The company discovers, develops and commercializes novel small molecule drugs in areas of unmet need that will dramatically extend and improve the lives of its patients.

https://www.markets.co/arqule-arql-receives-a-buy-from-roth-capital/